$19.61
3.40% yesterday
Nasdaq, Dec 01, 10:18 pm CET
ISIN
KYG8807B1068
Symbol
TBPH

Theravance Biopharma Inc Stock price

$19.61
+4.39 28.84% 1M
+8.46 75.87% 6M
+10.20 108.40% YTD
+10.17 107.73% 1Y
+8.81 81.57% 3Y
+2.38 13.81% 5Y
+0.39 2.03% 10Y
-3.35 14.59% 20Y
Nasdaq, Closing price Mon, Dec 01 2025
-0.69 3.40%
ISIN
KYG8807B1068
Symbol
TBPH
Industry

Key metrics

Basic
Market capitalization
$1.0b
Enterprise Value
$731.2m
Net debt
positive
Cash
$329.7m
Shares outstanding
50.7m
Valuation (TTM | estimate)
P/E
36.3 | 21.6
P/S
12.8 | 8.9
EV/Sales
9.1 | 6.3
EV/FCF
3.0
P/B
4.4
Financial Health
Equity Ratio
49.6%
Return on Equity
-32.1%
ROCE
-8.7%
ROIC
-25.6%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$80.3m | $115.8m
EBITDA
$-34.5m | -
EBIT
$-32.8m | $-14.7m
Net Income
$29.3m | $47.7m
Free Cash Flow
$243.5m
Growth (TTM | estimate)
Revenue
27.1% | 79.8%
EBITDA
-0.3% | -
EBIT
16.9% | 65.4%
Net Income
159.4% | 184.6%
Free Cash Flow
2,077.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-43.0% | -
EBIT
-40.9%
Net
36.5% | 41.2%
Free Cash Flow
303.1%
More
EPS
$0.6
FCF per Share
$4.8
Short interest
17.3%
Employees
97
Rev per Employee
$660.0k
Show more

Is Theravance Biopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Theravance Biopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Theravance Biopharma Inc forecast:

9x Buy
75%
3x Hold
25%

Analyst Opinions

12 Analysts have issued a Theravance Biopharma Inc forecast:

Buy
75%
Hold
25%

Financial data from Theravance Biopharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
80 80
27% 27%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 74 74
11% 11%
92%
- Research and Development Expense 40 40
8% 8%
49%
-35 -35
0% 0%
-43%
- Depreciation and Amortization -1.71 -1.71
134% 134%
-2%
EBIT (Operating Income) EBIT -33 -33
17% 17%
-41%
Net Profit 29 29
159% 159%
37%

In millions USD.

Don't miss a Thing! We will send you all news about Theravance Biopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Theravance Biopharma Inc Stock News

Neutral
PRNewsWire
11 days ago
DUBLIN , Nov. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that it will host a virtual key opinion leader (KOL) investor event on Monday, December 8, 2025 at 10:30 AM ET. To register, click here.
Neutral
PRNewsWire
13 days ago
DUBLIN , Nov. 19, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate in the following investor conferences in December 2025: 8th Annual Evercore Healthcare Conference Location: Coral Gables, FL Format: Fireside ChatDate: Thursday, December 4, 2025 Time: 8:20-8:40 AM ET Webcast Oppenheimer Movers in Rare Disease Summit Location: New Yo...
Positive
The Motley Fool
20 days ago
Yupelri's strength helped Theravance achieve non-GAAP profitability this quarter. The company is on track for lucrative milestones.
More Theravance Biopharma Inc News

Company Profile

Theravance Biopharma, Inc. operates as a biopharmaceutical company. It focuses on the discovery, research, development, and commercialization of organ-selective medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Head office Cayman Islands
CEO Rick Winningham
Employees 97
Founded 2013
Website www.theravance.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today